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Available online 28 February 2012Abstract Intravascular delivery of cells has been increasingly used in stroke models and clinical trials. We compared the
biodistribution and therapeutic effects of bone marrow mononuclear cells (BMMCs) delivered by intra-arterial (IA) or intra-
venous (IV) injection after cortical ischemia. For the biodistribution analyses, BMMCs were labeled with 99mTechnetium
(99mTc). At 2 h, gamma-well counting of the brain and of the other organs evaluated did not show differences between
the non-ischemic and ischemic groups or between injection routes, and the organs with the highest uptake were the liver
and lungs, with low uptake in the brain. At 24 h, the liver maintained the highest activity, and a marked decrease was
seen in pulmonary uptake in all groups. At this time point, although the activity in the brain remained low, the lesioned
hemisphere showed greater homing than the contralateral hemisphere, for both the IV and IA ischemic groups. Histological
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2 A. Vasconcelos-dos-Santos et al.transplantation and functional recovery was observed in both groups up to 11 weeks after the lesion. In conclusion, trans-
plantation of BMMCs by IA or IV routes may lead to similar brain homing and therapeutic efficacy after experimental stroke.
© 2012 Elsevier B.V. All rights reserved.Introduction
Stroke remains a leading cause of adult disability worldwide.
In Brazil it is the leading cause of death, with a mortality
rate of approximately 51.6 deaths per 100,000 inhabitants
(Garcia et al., 2009) and shows the highest case-fatality rate
in Latin America (Lotufo and Bensenor, 2009). Recently, cell-
based therapies have emerged as a promising tool for the
treatment of stroke (Baker et al., 2007; Hicks et al., 2009;
Lindvall and Kokaia, 2010; Ohtaki et al., 2008; Shimada and
Spees, 2011) and different cell types and routes have been
used in these studies. In order to be able to translate these re-
sults to a clinical setting, more information is required regard-
ing the safety and efficacy of the different cell types, doses,
and routes of administration. Therapy with BMMCs has led to
functional improvement in animal models of focal cerebral is-
chemia when the cells were transplanted either intravenously
or intra-arterially (Brenneman et al., 2010; de Vasconcelos
Dos Santos et al., 2010; Giraldi-Guimaraes et al., 2009; Iihoshi
et al., 2004; Nakano-Doi et al., 2010). Independent of the de-
livery route, several studies using labeled cells from different
tissues and species donors suggest the existence of a high rate
of cell entrapment in peripheral organs (Detante et al., 2009;
Fischer et al., 2009; Gao et al., 2001). Moreover, the number
of injected cells reaching the brain parenchyma seems to be
small (Detante et al., 2009; Lappalainen et al., 2008). Despite
the small number of cells found in the brain tissue, functional
effects have been observed in the cell-treated animals, sug-
gesting that peripheral mechanisms may play a systemic role
in cell therapy, i.e., the cells do not necessarily need to
reach the central nervous system in order to trigger their ther-
apeutic effects (Borlongan et al., 2004; Mendez-Otero et al.,
2007). In this respect, a careful evaluation of the biodistribu-
tion of the transplanted cells and a correlation with the func-
tional efficacy may provide a better understanding of the
mechanisms involved in the therapeutic effects observed. Nu-
clear Medicine techniques provide valuable means for moni-
toring cell therapies in vivo, with high image quality. In
addition, these techniques also allow us to estimate the num-
ber of cells in different organs and tissues by counting the ac-
tivity in the isolated organs (Detante et al., 2009; Lassance et
al., 2009; Quintanilha et al., 2008). Our working hypothesis is
that the effect of BMMCs may not depend on the intravascular
modality of administration. Therefore, the present study ex-
amined the therapeutic effect after IV and IA administrations
of BMMCs. We also investigated the distribution of these
cells, to determinewhether there are differences in effective-
ness between these routes of administration.Results
Whole-body nuclear imaging
Whole-body scintigraphies performed at 2 h after transplan-
tation indicated high activity in the head after IA injection, bothin ischemic (Figure 1) and non-ischemic groups (data not
shown). After IV injection, no marked uptake was seen in the
head in ischemic (Figure 1) or non-ischemic groups (data not
shown). High activity in the lungs, liver and kidneys was ob-
served in all groups in this time frame. Scintigraphy of the isolat-
ed brain, liver, spleen, kidneys, and lungs and of the head
without the brain showed a high uptake in the head of IA animals
and low uptake in the brain (Supplemental Figure 1).
After 24 h, the activity decreased significantly due to the 6-h
half-life of 99mTc, and the image resolution was poor. Neverthe-
less, a clear reduction could be observed in the lung uptake, and
activity was limitedmainly to the liver and kidneys in all groups.
Also, the activity in the head of intra-arterial groups observed at
2 h was no longer present (Figure 1).
Biodistribution by isolated organ gamma-well counting
At 2 h after 99mTc-BMMC transplantation, no difference in the
gamma-well counting was observed between non-ischemic
and ischemic groups or between intra-arterial and intravenous
injections in the different organs evaluated (Figure 2). The
total activity in the organs evaluated was approximately
55.2% of the injected dose and did not differ among groups.
Moreover, no difference in the activity was observed between
the right and left hemispheres at 2 h, in both ischemic and
non-ischemic groups (Figure 2). At 24 h, only 12.3% of the initial
activity injected remained in the organs, and the only organ
that showed a difference in distribution among groups was
the brain. At this time point, the left hemisphere showed
higher activity than the right hemisphere, for both the intrave-
nous (5.9±3.9×10−3%ID/g vs. 1.8±1.2×10−3% ID/g; p=0.0065;
paired t-test; Figure 3) and intra-arterial groups (4.2±
3.3×10−3%ID/g vs. 1.6±0.8×10−3%ID/g; p=0.0472; Figure 3).
In the non-ischemic animals, no difference in activity be-
tween hemispheres was seen (Figure 3). At 2 h, the organ
with the highest percentage of uptake in all groups was the
liver (32.5±4.5%), followed by the lungs (9.6±4.8%), kidneys
(8.7±4.2%) and spleen (3.3±1.5%). With respect to the per-
centage of uptake per gram of tissue, the lungs showed the
highest activity (5.7±3.4% ID/g), followed by the kidneys
(3.6±2.4% ID/g), spleen (3.4±1.6% ID/g) and liver (2.9±0.6%
ID/g). At 24 h, the organ with the highest percentage of up-
take was the liver (8.1±1.7%), followed by the kidneys (3.0±
1.3%) and spleen (0.86±0.2%). With respect to the percentage
of uptake per gram of tissue, the kidneys showed the highest
activity (1.3±0.7% ID/g), followed by the spleen (1.0±0.2%
ID/g) and liver (0.6±0.1% ID/g). The high activity in the lungs
observed in in vivo images and quantified in gamma-well
counting indicated an initial trapping at 2 h and a delayed re-
distribution at 24 h, with a decrease of 97% of its initial up-
take, the greatest among the organs studied.
BMMCs in the periphery of the ischemic lesion
To evaluate whether the uptake in the brain in the gamma-
well counting was indeed correlated with the presence of
Figure 1 Representative whole-body images demonstrating the biodistribution of BMMCs labeled with 99mTc, 2 h and 24 h (n=6 for
each group) after intravenous or intra-arterial injection in ischemic rats. The intra-arterial group had significant activity in the head
at 2 h. The remaining activity could be seen in the lungs, liver, kidneys and bladder in all groups at 2 h, and in the liver and kidneys at
24 h.
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the BMMCs with CellTrace and performed a histological
analysis. A small number of labeled BMMCs were found
only in the infarct and peri-infarct regions 24 h after trans-
plantation, and no cells were found in the contralateral
hemisphere. Figure 4A shows a photomicrograph demon-
strating fluorescence-labeled BMMCs that migrated to the
cerebral peri-infarct parenchyma. Cells could not be quan-
tified in the lesion core due to the formation of the cavita-
tion. There was no difference in the number of CellTrace-
labeled BMMCs in ischemic animals 24 h after IV and IA
transplantations (Figure 4B).Figure 2 Distribution of BMMCs labeled with 99mTc 2 h (A) and 24 h
(n=4) and ischemic rats (n=6) by gamma-well counting. Tracer act
(%dose/organ; A and B) and dose per gram of organ (%ID/g; C and DBMMCs promote therapeutic effects independent of
the administration route
We have previously demonstrated functional recovery
after intravenous transplantation of BMMCs in an animal
model of cortical ischemia (de Vasconcelos Dos Santos et
al., 2010; Giraldi-Guimaraes et al., 2009). In the present
study, we investigated whether there are differences in
therapeutic efficacy between intra-arterial and intravenous
administration routes. To answer this question, we used the
cylinder test to assess functional recovery (Schallert, 2006;
Schallert et al., 2001). This test is a sensitive tool to(B) after intravenous or intra-arterial injection in non-ischemic
ivity is expressed as the percentage of injected dose per organ
).
Figure 3 Brain distribution of BMMCs labeled with 99mTc, 2 h (A) and 24 h (B) after intravenous or intra-arterial injection in
non-ischemic (n=4) and ischemic (n=6) rats by gamma-well counting. Tracer activity is expressed as the percentage of injected
dose per gram of organ (%ID/g) * pb0.05 paired t-test.
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model of ischemia (de Vasconcelos Dos Santos et al., 2010;
Giraldi-Guimaraes et al., 2009). We observed significant
functional improvement after administration of BMMCs in
both groups, independent of the route of administration
(Figure 5). The pre-ischemia score showed no asymmetry be-
fore lesion induction, as expected, whereas, 1 day after le-
sion, all ischemic animals showed clear asymmetry in the
use of the forelimbs, preferentially using the limb ipsilateral
to the cortical lesion, and were therefore not affected by
the procedure (Figure 5). BMMCs were administered 1 PID,
and from the 6th day after injection, evident recovery of
sensorimotor function was observed in both the IA and IV
groups. The repeated measures two-way ANOVA comparing
the treated groups with the saline group revealed significant
effects of time (F=34.91; pb0.0001), treatment (F=48.08;
pb0.0001), and interaction between time and treatment
(F=6780; pb0.0001). The analysis with two-way ANOVA
and Bonferroni post-test showed significant differences in
the symmetry score between the treated groups (IA and IV)
and the saline group at each PID starting 7 days after ische-
mia (Supplemental Figure 2).Discussion
An ever-increasing number of reports have demonstrated
that in animal subjects, BMMCs improve functional outcome
after ischemia (Baker et al., 2007; Brenneman et al., 2010;
Giraldi-Guimaraes et al., 2009; Iihoshi et al., 2004; Kamiya
et al., 2008). More recently, these cells have also been eval-
uated for safety and feasibility in clinical trials in patients
with stroke (Battistella et al., 2011; Mendez-Otero et al.,
2007; Mendonça et al., 2006). In these studies, the cells
were delivered intra-arterially by a catheter in the middlecerebral artery, and the results showed that no patients
exhibited adverse effects after transplantation, or worsen-
ing in neurological performance. However, IA injection re-
quires a cerebral angiography, an invasive procedure that
involves infrequent but significant risks, including new
strokes. A retrospective study reviewing cerebral angiogra-
phies in nearly 20,000 patients has indicated that the risk
of complications due to the procedure is approximately 2%
and that the risk of a new stroke is approximately 0.14%
(Kaufmann et al., 2007). Besides the intrinsic risks of a cere-
bral angiography, it is possible that the injection of cells may
create risks such as embolisms. A preclinical study using
MSCs found that despite the benefits of intra-arterial deliv-
ery of stem cells to the ischemic brain, there was a clear
risk of vascular occlusion and also a large increase in mortal-
ity (67% for IA transplantation compared to 7% in non-
transplanted animals) (Walczak et al., 2008). Similarly, Li
et al. observed a high mortality rate (41%) after IA adminis-
tration, compared with intra-cerebral (17%) and IV (8%), in-
dicating that IV administration may be safer than the other
routes (Li et al., 2010). On the other hand, a study that per-
formed IA administration of BMMCs did not show alteration in
the cerebral perfusion, suggesting that this effect may be re-
lated to the type of transplanted cells (Brenneman et al.,
2010). Even if the IA route is shown to provide greater hom-
ing in the lesion, more studies are required to elucidate if
the IA route is more effective than the IV and of comparable
safety. This is especially relevant when considering that dif-
ferent groups have suggested that the effect of cell therapy
in stroke may not be directly related to the presence of cells
in the brain, since it is possible to observe functional recov-
ery without the presence of cells in the cerebral parenchyma
(Borlongan et al., 2004) or with few cells, as shown by stud-
ies involving different types of cell therapies after IA or IV
administration (Bacigaluppi et al., 2009; Brenneman et al.,
Figure 4 BMMCs in the periphery of the injury. Fluorescence
photomicrography of the lesioned ipsilateral hemisphere 24 h
after transplantation of CellTrace-labeled BMMCs (red; A).
Both IV and IA (n=4 for each group) treated animals showed sim-
ilar numbers of BMMCs in the peri-infarct, as shown in the graph
(B). Nuclei were visualized with Sytox green (green). Scale bar:
20 μm.
Figure 5 Intravenous and intra-arterial administrations of
BMMCs showed a similar level of functional recovery in the cylin-
der test. Analysis of the sensorimotor function in the cylinder
test showed a significant recovery of the impaired forelimb in
both IA (n=5) and IV (n=8) groups compared with the saline
group (n=5 IA, n=5 IV). This effect was maintained for
11 weeks, corresponding to the period studied, and no signifi-
cant difference was observed between the IA and IV groups.
Data shown in the graph are means±S.E.M. (*) and (#) represent
comparisons of the IV and IA groups respectively, with the saline
groups. ***=pb0.001, ##=pb0.01; Bonferroni post-test.
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of the possible involvement of other organs, and mainly to
compare the distribution between the IA and IV routes, we
labeled the BMMCs with 99mTc. Intense uptake in the head
was detected by the whole-body scintigraphies, showing
that transplanted cells reached some tissue either inside
the brain or in other surrounding structures. Surprisingly,
scintigraphy analysis of the head and other organs after re-
moval of the brain, revealed that the high uptake continued
in the head 2 h after the transplant. Analysis by gamma-well
counting in the isolated organs confirmed that the high ac-
tivity in the head observed in the whole-body images did
not occur in the brain of the animal that received IA injec-
tion. Histological analysis after CellTrace labeling also indi-
cated a small number of BMMCs in the peri-infarct area,
after both IA and IV injections, whereas no cells were
found in non-ischemic animals. Moreover, analysis of the ra-
dioactivity in the isolated organs indicated that IV and IA in-
fusions led to similar distributions in the different organs in
both non-ischemic and ischemic animals. The only organ
that showed a difference was the brain, where ischemicanimals had greater activity than non-ischemic animals in
the lesioned (left) hemisphere compared to the non-
lesioned (right) hemisphere at 24 h, and this occurred after
both IV and IA injections. These two pieces of data together
suggest that a significant part of the transplanted cells may
have homed to a tissue outside the brain but still within
the head. A potential explanation is that since the injection
was made in the common carotid artery, a significant
amount of cells could have been distributed along the tissue
irrigated by the external carotid artery, such as the naso-
pharynx region. Importantly, 24 h after the transplant, the
strong signal was no longer present in the head of the IA
group, indicating that the homing to this region was transito-
ry. The amount of cells that migrated to the brain at 2 h and
24 h was very small, which is in accordance with previous
studies (Detante et al., 2009; Gao et al., 2001) and suggests
that cells may not need to remain in the brain to generate
functional improvement. In a previous study, we demon-
strated a therapeutic window for IV administration of
BMMCs up to 7 days after injury, with a better outcome
when the cells were injected 1 day post-ischemia (de
Vasconcelos Dos Santos et al., 2010). In that report, the
treated animals reached a score of approximately 80% func-
tional recovery. In an attempt to investigate whether the IA
delivery could overcome this effect, we evaluated this pro-
cedure with IV administration, using the optimum time win-
dow and dose identified in the previous studies. Our results
showed that there was no significant difference in the effi-
cacy of the therapy between the animal groups that re-
ceived IA and IV, and both showed functional improvement
compared with the control (saline-treated) group. Different
results were reported by Kamiya et al. (2008). In their study,
IA administration of BMMCs led to a decrease in total infarct
volume and improvement in motor function, as assessed with
a rotarod test, when compared to the vehicle group, and this
6 A. Vasconcelos-dos-Santos et al.effect was not seen in the IV group. The data in Kamiya and
colleagues' report were generated from the analysis of ani-
mals in which transient ischemia was performed by middle
cerebral artery occlusion (MCAO), differently from our
study, where the lesion was restricted to the cerebral cortex
by thermocoagulation (TCL), which causes a permanent is-
chemia. Additionally, the number of injected cells used in
our model was 3 times higher than the number used by
Kamiya and colleagues, and the injection was performed
24 h after the ischemia, instead of immediately after the
transient MCAO. Furthermore, Kamiya's group conducted
the histological analysis at an earlier time point, 1 h after
the re-perfusion, and initially entrapped cells may no longer
persist at subsequent time points. These differences may be
responsible for the conflict in findings between our reports.Conclusions
To our knowledge, this is the first study to compare IA and IV
routes of administration of BMMCs for the therapy of cortical
ischemia, produced in a model of thermocoagulation, in
terms of biodistribution and efficacy. Twenty-four hours
after cell transplantation, homing in the brain seems to be
comparable between both routes in ischemic animals as an-
alyzed by 99mTc and CellTrace labeling, and greater than
that of non-ischemic animals. Moreover, the functional stud-
ies indicate a similar recovery of the sensorimotor function,
as evaluated by the cylinder test, up to 11 weeks post-
ischemia after IV or IA BMMC therapy.Material and methods
Animals
Experiments were performed in adult male Wistar rats (3 to
5 months old) weighing 250 to 450 g. Our experiments were
carried out in accordance with the National Institutes of
Health Guide for the Care and Use of Laboratory Animals
(NIH Publication No. 80-23), and were approved by the Insti-
tutional Committee for the Use of Experimental Animals
(IBCCF 076).Surgery
The ischemic lesion was induced by thermocoagulation of
the blood in the pial blood vessels of sensorimotor cortices,
as described previously (Szele et al., 1995). Briefly, the ani-
mals were anesthetized with ketamine hydrochloride
(50 mg/kg, i.p.) and xylazine hydrochloride (10 mg/kg,
i.p.) and placed in a stereotactic frame. The skull was surgi-
cally exposed and a craniotomy was performed, exposing the
left frontoparietal cortex (+2 to −6 mm A.P. from the Breg-
ma). The blood in the pial vessels was thermocoagulated
transdurally by bringing a hot probe close to the dura
mater. The color of the blood vessels is normally light red,
and we considered the blood completely thermocoagulated
after it turned to dark red. Care was taken to avoid touching
and tearing the dura mater. After the procedure, the skin
was sutured and the animals were kept warm under a heatlamp and returned to the colony room after they recovered
from the anesthesia.Obtaining BMMCs
BMMCs were isolated from the tibias and femurs of normal
syngeneic donor rats. Briefly, bone marrow was aspirated
from the bones and dissociated with serum-free DMEM-F12
(GIBCO BRL, Grand Island, NY, USA) and collected in sterile
tubes. Bone-marrow cells were then mechanically dissociat-
ed, centrifuged for 5 min (250×g), and resuspended in 4 ml
of DMEM-F12. This volume was gently added over 4 m of His-
topaque 1083 (Sigma-Aldrich, São Paulo, Brazil) and centri-
fuged for 30 min (400×g). The cells were collected from
the mononuclear cell layer and washed with phosphate-
buffered saline (PBS), pH 7.4 in three consecutive series of
centrifugations at 250×g (5 min). Following a final centrifu-
gation, approximately 3×107 BMMCs were suspended in
500 μl of saline and either injected immediately in the ani-
mals submitted to the behavior test, or labeled for distribu-
tion analysis.BMMC labeling
BMMCs were labeled with 99mTc following protocols de-
scribed previously (Barbosa da Fonseca et al., 2010;
Battistella et al., 2011; Carvalho et al., 2008; Lassance et
al., 2009; Quintanilha et al., 2008). Briefly, 500 μl of sterile
SnCl2 solution was added to the cell suspension in phosphate-
buffered saline (PBS), and the mixture was incubated at
room temperature for 10 min. Then, 5 mCi 99mTc was
added and the incubation continued for another 10 min.
After centrifugation (500×g for 5 min), the supernatant
was removed and the cells were washed three times with
PBS. Viability of the labeled cells was assessed by the trypan
blue exclusion test, and was estimated to be greater than
93% in all cases. Labeling efficiency (%) was calculated by
the activity in the pellet divided by the sum of the radioac-
tivity in the pellet plus supernatant, and was estimated
to be greater than 90% in all cases. Approximately 3×107
99mTc-BMMCs were injected in ischemic rats (1 day after is-
chemia) and non-ischemic rats through the jugular vein (IV)
and common carotid artery (IA), immediately after labeling.
For histochemical analyses, the BMMCs were incubated with
CellTraceTM Far Red DDAO-SE (Invitrogen) diluted in DMEM
(1:500) for 45 min at 37 °C in a 5% CO2 incubator. The
same amount of cells (3×107 99mTc-BMMCs) was injected in
ischemic animals by IV (n=4) and IA (n=4) routes after Cell-
Trace labeling. Twenty-four hours after transplantation,
the animals were euthanized and fixed with 4% paraformal-
dehyde. Three sequential coronal slices were obtained
from three distinct antero-posterior regions (2.2, 1.0, and
0.4 mm from the Bregma). CellTrace-positive cells were
counted in the photomicrographs obtained from the entire
periphery of the lesion, by confocal microscopy. The photo-
micrographs were taken using a 20× objective, averaged
across the 6–7 photomicrographs in each of the slices.
Counts were made in a double-blind manner, and the statis-
tical analysis was done using GraphPad Prism 5.02
(1992–2004 GraphPad Software, Inc.), using a paired t-test.
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Whole-body nuclear imaging was performed for qualita-
tive biodistribution in a GE Millennium Gamma Camera (Gen-
eral Electric Medical Systems, Milwaukee, Wisconsin, USA)
equipped with a high-resolution collimator. A 15% energy
window centered on the 140 keV photo peak of 99mTc was
used. At 2 h and 24 h after transplantation, animals were di-
vided into two major experimental groups, ischemic (n=6)
and non-ischemic (n=4), receiving injection of 99mTc-
BMMCs by IA or IV route, in a total of 8 groups (supplemental
Figure 2). For quantitative biodistribution analysis, immedi-
ately after whole-body nuclear imaging, the rats were eu-
thanized and the left and right cerebral hemispheres,
heart, lungs, liver, kidneys, spleen and stomach were re-
moved and weighed. A scintigraphy of the isolated brain,
heart, liver, spleen, kidneys, lungs, and stomach and of the
head without the brain was also performed in the ischemic
animals 2 h after cell injection. The total radioactivity
injected in each animal and the remaining radioactivity in
each organ were measured in a gamma counter (Cobra II
Auto-Gamma, Packard, USA). The percentage of the dose
per organ [% dose/organ: each organ counts/total injected
activity×100] and the injected dose (ID) per gram of tissue
[%ID/g:% dose/organ/mass (g)] were determined for each
sample.
Behavioral testing
Functional recovery was evaluated using the cylinder test
(Schallert, 2006; Schallert et al., 2001), which allows mea-
surement of forelimb use asymmetry. The analyses were
performed by blinded investigators to avoid bias. Animals
of all experimental groups were subjected to one trial on
the pre-ischemic day and then weekly until 77 post-
ischemic days (PID). The trial consisted of placing the animal
inside a glass cylinder (20 cm in diameter and 30 cm in
height). To prevent habituation to the cylinder, the number
of movements recorded in any one trial was limited to 20.
The occurrences of sole use of the ipsilateral (to the lesion)
or contralateral forelimb or the simultaneous use of both
forelimbs were counted. For each animal on each of the ex-
amined PIDs, the percentage relative to the total number of
uses (ipsilateral+contralateral+simultaneous) was calculat-
ed for the ipsilateral (unimpaired) uses and for the contra-
lateral (impaired) uses. Then, one asymmetry score for
each animal was calculated on each PID by the following for-
mula: asymmetry score=(% of ipsilateral uses)− (% of contra-
lateral uses). Following this, the asymmetry score was
converted to the symmetry score (100−asymmetry score).
The animals submitted to functional evaluation were tested
before the ischemia, 1 PID, when they received the trans-
plant, and weekly until 11 weeks.
Statistical analysis
For statistical analysis of the behavioral tests, repeated
measures two-way ANOVA was used for comparison among
groups. Because a significant interaction was observed in
the cylinder test, a Bonferroni post-test was performed foreach PID. The level of significance was always set at
pb0.05. The biodistribution was analyzed using the paired
t-test.Supplementary materials related to this article can be
found online at doi:10.1016/j.scr.2012.02.002.References
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